Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor
|ClinicalTrials.gov Identifier: NCT01576211|
Recruitment Status : Completed
First Posted : April 12, 2012
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood and tissue from newborns and from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies cord blood and placenta tissue from newborns, and tumor tissue samples from patients with Wilms tumor.
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Genetic: DNA methylation analysis Genetic: RNA analysis Genetic: allele-specific oligonucleotide real-time quantitative polymerase chain reaction Genetic: gene expression analysis Genetic: nucleic acid sequencing Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- What is the frequency of loss of imprinting at birth (in the cord blood and placenta) in a relatively healthy birth cohort?
- Does deoxyribonucleic acid (DNA) methylation levels at imprinting genes have a direct association to the gene expression?
OUTLINE: Archived tumor tissue, cord blood, and placenta samples are analyzed for DNA methylation, single nucleotide polymorphism, and gene expression by polymerase chain reaction (PCR), pyrosequencing, and quantitative real-time PCR. Information regarding gender and age of the samples are also collected, if possible.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Observational Model:||Case Control|
|Official Title:||Investigating the Frequency of Loss of Imprinting Across a Birth Cohort and the Link DNA Methylation Plays|
|Study Start Date :||April 2012|
|Primary Completion Date :||May 2016|
- Frequency of loss of imprinting at birth
- Association between methylation levels and gene expression
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01576211
|Principal Investigator:||Karin Michels, MD, PhD||Dana-Farber/Brigham and Women's Cancer Center|